Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong
· Delayed Price · Currency is HKD
214.40
+5.40 (2.58%)
Jun 6, 2025, 4:08 PM HKT
Duality Biotherapeutics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Net Income | -1,050 | -357.51 |
| Depreciation & Amortization | 6.61 | 4.76 |
| Other Amortization | 1.26 | 0.23 |
| Asset Writedown & Restructuring Costs | 21.35 | - |
| Loss (Gain) From Sale of Investments | - | 1.16 |
| Stock-Based Compensation | 190.41 | 23.96 |
| Other Operating Activities | 855.93 | 903.91 |
| Change in Accounts Receivable | -276.77 | -120.97 |
| Change in Accounts Payable | 463.06 | 154.46 |
| Change in Unearned Revenue | 112.21 | 216.3 |
| Change in Other Net Operating Assets | -37.86 | -9.95 |
| Operating Cash Flow | 285.78 | 816.34 |
| Operating Cash Flow Growth | -64.99% | - |
| Capital Expenditures | -4.08 | -11.28 |
| Sale (Purchase) of Intangibles | -27.1 | -24.62 |
| Investment in Securities | -179.71 | - |
| Other Investing Activities | -0.26 | -42.65 |
| Investing Cash Flow | -211.15 | -78.55 |
| Long-Term Debt Repaid | -3.4 | -3.5 |
| Net Debt Issued (Repaid) | -3.4 | -3.5 |
| Other Financing Activities | -4.22 | -1.59 |
| Financing Cash Flow | -7.62 | 10.82 |
| Foreign Exchange Rate Adjustments | 11.01 | 6.31 |
| Net Cash Flow | 78.02 | 754.92 |
| Free Cash Flow | 281.7 | 805.05 |
| Free Cash Flow Growth | -65.01% | - |
| Free Cash Flow Margin | 14.51% | 45.06% |
| Free Cash Flow Per Share | 35.21 | 100.63 |
| Cash Interest Paid | 0.25 | 0.19 |
| Cash Income Tax Paid | 54.54 | 248.93 |
| Levered Free Cash Flow | 1,045 | - |
| Unlevered Free Cash Flow | 1,045 | - |
| Change in Net Working Capital | -995.11 | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.